AstraZeneca通过法院命令阻止药剂师在澳大利亚推出非专利糖尿病药物, AstraZeneca blocked Pharmacor’s generic diabetes drug launch in Australia with a court order, protecting its patent until a full trial.

AstraZeneca在赢得联邦法院的一项中间禁令后, 阻止药剂师在澳大利亚推出其糖尿病药物(dapagliflozin)的通用版本。 AstraZeneca has blocked Pharmacor from launching a generic version of its diabetes drug dapagliflozin in Australia after winning an interlocutory injunction from the Federal Court. 该命令由Kylie Downes法官发布,在全面审判之前停止销售和分发,并要求药剂师撤回或修改其申请,以便列入药品福利计划。 The order, issued by Justice Kylie Downes, halts sales and distribution until a full trial, and requires Pharmacor to withdraw or amend its applications for inclusion in the Pharmaceutical Benefits Scheme. 此举保护了2027年10月到期的AstraZeneca专利,并反映了创新制药商和通用制造商之间在市场准入和知识产权问题上持续的法律紧张。 The move protects AstraZeneca’s patent, which expires in October 2027, and reflects ongoing legal tensions between innovator drugmakers and generic manufacturers over market access and intellectual property rights.